牛巴貝西蟲免疫熒光試劑盒

babesia bovis IFA Kit

廣州健侖生物科技有限公司

主要用途：用于檢測(cè)牛血清中的牛巴貝西蟲IgG/IgM抗體

產(chǎn)品規(guī)格：12 孔/張,10 張/盒

主要產(chǎn)品包括：包柔氏螺旋體菌、布魯氏菌、貝納特氏立克次體、土倫桿菌、鉤端螺旋體、新型立克次體、恙蟲病、立克次體、果氏巴貝西蟲、馬焦蟲、牛焦蟲、利什曼蟲、新包蟲、弓形蟲、貓流感病毒、貓冠狀病毒、貓皰疹病毒、犬瘟病毒、犬細(xì)小病毒等病原微生物的 IFA、MIF、ELISA試劑。

牛巴貝西蟲免疫熒光試劑盒

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無(wú)形體、蜱蟲、恙蟲、利什曼原蟲、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-3室
【企業(yè)文化】

Benz認(rèn)為這一研究將能被用于臨床試驗(yàn)設(shè)計(jì)，尤其是希望能通過(guò)腫瘤基因組重分類，尋找新的治療方法的患者，“雖然需要后續(xù)的研究來(lái)驗(yàn)證，并完善這一新提出的癌癥分類系統(tǒng)，但是這項(xiàng)研究zui終將能為個(gè)性化癌癥醫(yī)療時(shí)代的到來(lái)，奠定基礎(chǔ)生物學(xué)基礎(chǔ)。”
盡管目前正在開發(fā)各種化合物對(duì)抗癌癥，但它們都具有嚴(yán)重的副作用。此外，腫瘤能夠?qū)@些化合物產(chǎn)生耐藥。
為了抵消上述兩個(gè)缺點(diǎn)，科學(xué)家們?cè)O(shè)計(jì)了一種基于肽的新療法，利用黃蜂毒液中的多肽，作為預(yù)防抗原抗體癌的潛在新方法。
這種肽具有在細(xì)胞質(zhì)膜形成孔的能力，并穿透進(jìn)入癌細(xì)胞，或誘導(dǎo)癌細(xì)胞壞死或觸發(fā)凋亡，zui后導(dǎo)致癌細(xì)胞死亡。
然而，這種強(qiáng)大的“自然武器”目前還不能用于治療，這是由于它的高毒性和缺乏細(xì)胞特異性，它不僅會(huì)損害腫瘤細(xì)胞，也將影響患者的健康細(xì)胞。因此，研究人員設(shè)計(jì)一種手段，以一個(gè)特定的和可控制的方式輸送肽到腫瘤，并使其在腫瘤細(xì)胞中堆積。
該系統(tǒng)由裝載兩個(gè)“組件”的載體聚合物組成：能綁定到腫瘤細(xì)胞受體的肽和黃蜂毒液的毒性肽。體外實(shí)驗(yàn)表明，黃蜂毒液的毒性肽被充分地遞送分布在腫瘤細(xì)胞內(nèi)，并導(dǎo)致其死亡，而正常細(xì)胞如紅細(xì)胞不受影響。

Benz believes the study will be used in clinical trial design, especially in patients wishing to reclassify the tumor genome to find new treatments, "although follow-up studies are needed to validate and refine the newly proposed cancer classification System, but the research will ultimay lay the foundations of basic biology for the advent of the personalized cancer care era. "
Although various compounds are currently being developed to combat cancer, they all have serious side effects. In addition, tumors can become resistant to these compounds.
In order to counteract the above two drawbacks, scientists have designed a new peptide-based therapy that uses the polypeptide in wasp venom as a potential new method of preventing antigen-antibody cancer.
This peptide has the ability to form pores in the plasma membrane and penetrates into cancer cells, induces necrosis or triggers apoptosis in cancer cells, and ultimay leads to the death of cancer cells.
However, this powerful "natural weapon" is currently not available for treatment due to its high toxicity and lack of cell specificity, which not only damages tumor cells but also affects healthy cells in patients. Therefore, the researchers devised a means to deliver the peptide to the tumor in a specific and controlled manner and allow it to accumulate in the tumor cells.
The system consists of a carrier polymer loaded with two "assemblies": a toxic peptide that binds to a tumor cell receptor peptide and wasps venom. In vitro experiments showed that the virulent peptide of the wasp venom is sufficiently delivered to distribute within the tumor cells and cause its death, whereas normal cells such as red blood cells are unaffected.